Efficacy and safety of monthly ibandronate in men with low bone density
Authors:
- Eric S. OrwollEOEric S. Orwoll
- Neil C. BinkleyNBNeil C. Binkley
- E. Michael LewieckiELE. Michael Lewiecki
- Ugis GruntmanisUGUgis Gruntmanis
- Michael A. FriesMFMichael A. Fries
- Gorana DasicGDGorana Dasic
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
- Roche
This publication has 24 references indexed in Scilit:
- Loss of Hip BMD in Older Men: The Osteoporotic Fractures in Men (MrOS) StudyJournal of Bone and Mineral Research, 2009
- Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter StudyJournal of Bone and Mineral Research, 2009
- Osteoporosis in MenEndocrine Reviews, 2008
- Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION studyCurrent Medical Research and Opinion, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE studyAnnals of the Rheumatic Diseases, 2006
- Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONECurrent Medical Research and Opinion, 2005
- Ibandronate: A Clinical Pharmacological and Pharmacokinetic UpdateThe Journal of Clinical Pharmacology, 2004
- Alendronate for the Treatment of Osteoporosis in MenNew England Journal of Medicine, 2000
- Effect of Calcium and Vitamin D Supplementation on Bone Density in Men and Women 65 Years of Age or OlderNew England Journal of Medicine, 1997